ClinicalTrials.gg
RecruitingNCT07148999Updated Sep 29, 2025

An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera

A Phase 1/2 interventional study of Opt-IVF and Control in Infertility (IVF Patients), sponsored by Urmila DIwekar. Recruiting at 2 sites in United States. Open to female participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Urmila DIwekar · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.

Planned enrollment
73rd of 274
200 · median 84
Started
2025
with 20 others
Phase 1/2
5 of 395
1 open now
Primary completion
2026-02
later than 16 of 82 live
Registered
377th of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 73rd largest by planned enrollment of the 274 interventional ones that give a count, is one of 21 that started in 2025, is one of 5 in phase 1/2, reaches primary completion later than 16 of the 82 other live ones, and was the 377th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

A clinical trial will determine the effectiveness of using the Opt-IVF decision support tool for each patient's personalized and optimal drug dosage profile in the United States.

Read the detailed description

This will be a two-arm randomized clinical trial involving more than 100 patients; one arm will undergo superovulation using dosages predicted by the decision support tool, while the other will undergo the current standard treatment. The research question is whether outcomes of patient dosage treatment using Opt-IVF are better or similar to the current practice. We will compare the outcomes of the two groups of patients in terms of the numbers and percentage of mature follicles retrieved at the end of each cycle, total FSH and HMG dosages used, and the number of required testing days for that cycle, total number of M2s, Number of embryos, Number of Grade A embryos and Number of Grade A blastocysts.

The trial is for research purposes only. The current tool has not been submitted for any regulatory body approval.

03

Conditions studied

  • Infertility (IVF Patients)

Browse trials for

Keywords

  • Opt-IVF
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infertile women

Exclusion criteria

Exclusion Criteria:

All female patients who will not undergo IVF or whose cycles will be converted to IUI. Male patients will not be enrolled in this study. No donor cycles.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Control

    This arm will get dosage prescribed by the doctor

    Other: Control

  • Experimental
    Opt-IVF

    This arm patients will get dosage provided by Opt-IVF

    Combination Product: Opt-IVF

Interventions

  • Combination productOpt-IVF

    Opt-IVF provides optimized dosage profile for each patient

  • OtherControl

    Physicians will decide the dosage for each day for patients

06

What researchers measure

Primary outcomes

  1. Total Gonadotropin Dosage

    Total Gonadotropin Dosage for the cycle

    Time frame: Two weeks after the start of the cycle

  2. Total Oocytes Retrieved

    Total Oocytes Retrieved

    Time frame: Two weeks after the start of the stimulation cycle

  3. M2 Oocytes

    Total M2 Oocytes

    Time frame: Two weeks after the start of the stimulation cycle

  4. Total Embryos Formed

    Total Embryos Formed

    Time frame: Two weeks after the start of stimulation cycle

  5. Grade A embryos/Blastocytes

    Grade A Day 3 Embryos or Grade A Day 5 Blastocytes

    Time frame: Three weeks after the start of stimulation cycle

Secondary outcomes

  1. Pregnancy Rates

    Cycle pregnancy rate till the first transfer

    Time frame: one month after first transfer

07

Study locations

2 of 2 sites recruiting
  • Positivf Fertility
    Houston, Texas 77054, United States
    Recruiting
  • Positivf Fertility
    San Antonio, Texas 78249, United States
    Recruiting
08

References and documents

Publications

  • Diwekar et al., A multicenter randomized clinical trial with a novel decision support tool to improve IVF success, Reproduction and Fertility, 6(3), e250004, 2025.DOI: https://doi.org/10.1530/RAF-25-0004
  • Diwekar U, Gupta S, Gahlan A, Hota S, Murdia K, Murdia N, Chandra V, Bhoi N, Joag S. A new decision-support tool in a multi-center randomized trial for personalized, optimized, and simplified fertility treatment in non-PCOS patients. Reprod Fertil. 2024 Sep 16;5(3):e240013. doi: 10.1530/RAF-24-0013. Print 2024 Jul 1. PubMed 39159260 ↗
  • Nisal A, Diwekar U, Bhalerao V. Personalized medicine for in vitro fertilization procedure using modeling and optimal control. J Theor Biol. 2020 Feb 21;487:110105. doi: 10.1016/j.jtbi.2019.110105. Epub 2019 Dec 3. PubMed 31809718 ↗

Individual participant data

Plan to share: Yes — Data will be available by contacting Dr. Urmila Diwekar

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After completion of the trial

Access criteria: by contacting Dr. Diwekar

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Feb 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 29, 2025
StartEst.
Sep 23, 2025
Primary completionEst.
Feb 15, 2026
CompletionEst.
Feb 15, 2026
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07148999
Lead sponsor
Urmila DIwekar
Collaborators
IVF Academy of USA, Positivf Fertility
Responsible party
Urmila DIwekar (President, Stochastic Research Technologies LLC) — Sponsor-investigator
First posted
Aug 29, 2025
Start date
Sep 23, 2025 (estimated)
Primary completion
Feb 15, 2026 (estimated)
Completion
Feb 15, 2026 (estimated)
Last update
Sep 29, 2025

Study contacts

Urmila Diwekar, Ph.D.
Contact
urmila@vri-custom.org
6308863047
Sanjay Joag, M.D., Ph.D.
Contact
sanjay@opt-ivf.com
6305014451
Paul Magarelli, M.D., Ph.D.
principal investigator · IVF Academy USA
Francesco Arredondo, MD, Ph.D.
study director · Positivf Fertility

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion